Cantor Fitzgerald Initiates Coverage on MDRNA (MRNA) with a Buy - Share Poised to Open Higher
MRNA Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Cantor Fitzgerald initiates coverage on MDRNA (Nasdaq: MRNA) with a Buy. Price target $4.
Cantor analyst says, "MDRNA, an emerging RNAi company, we think, is positioned to expand its product pipeline and business via strategic partnering, ramping from the foundation management rapidly established earlier this year...MDRNA rapidly secured two major pharma deals with Roche and Novartis that we consider validating of the company's technology and capabilities. Further, we expect management to continue delivering deals with major pharmas that we believe would provide additional validation (and cash) of MDRNA's technology platforms and competencies."
To see more analyst ratings on MRNA Click Here.
MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi).
Cantor analyst says, "MDRNA, an emerging RNAi company, we think, is positioned to expand its product pipeline and business via strategic partnering, ramping from the foundation management rapidly established earlier this year...MDRNA rapidly secured two major pharma deals with Roche and Novartis that we consider validating of the company's technology and capabilities. Further, we expect management to continue delivering deals with major pharmas that we believe would provide additional validation (and cash) of MDRNA's technology platforms and competencies."
To see more analyst ratings on MRNA Click Here.
MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi).
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Wunderlich Securities Starts United Stationers (USTR) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
